Calidi Biotherapeutics Inc (CLDI) concluded trading on Thursday at a closing price of $0.46, with 0.47 million shares of worth about $0.21 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -55.90% during that period and on April 17, 2025 the price saw a loss of about -0.43%. Currently the company’s common shares owned by public are about 28.47M shares, out of which, 26.60M shares are available for trading.
Stock saw a price change of 13.48% in past 5 days and over the past one month there was a price change of -42.51%. Year-to-date (YTD), CLDI shares are showing a performance of -59.74% which decreased to -77.64% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.35 but also hit the highest price of $4.90 during that period. The average intraday trading volume for Calidi Biotherapeutics Inc shares is 1.23 million. The stock is currently trading -15.44% below its 20-day simple moving average (SMA20), while that difference is down -43.70% for SMA50 and it goes to -63.55% lower than SMA200.
Calidi Biotherapeutics Inc (AMEX: CLDI) currently have 28.47M outstanding shares and institutions hold larger chunk of about 3.83% of that.
The stock has a current market capitalization of $15.55M and its 3Y-monthly beta is at 1.20. It has posted earnings per share of -$3.69 in the same period. It has Quick Ratio of 1.08 while making debt-to-equity ratio of 4.60. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CLDI, volatility over the week remained 16.51% while standing at 15.01% over the month.
Analysts are in expectations that Calidi Biotherapeutics Inc (CLDI) stock would likely to be making an EPS of -0.15 in the current quarter, while forecast for next quarter EPS is -0.11 and it is -0.32 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.15 which is -0.15 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -1.98 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 84.85% while it is estimated to increase by 28.89% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on November 22, 2023 offering a Buy rating for the stock and assigned a target price of $11 to it. Coverage by Robert W. Baird stated Calidi Biotherapeutics Inc (CLDI) stock as an Outperform in their note to investors on October 09, 2023, suggesting a price target of $9 for the stock.
